Skip to main content

Advertisement

Table 1 Baseline characteristics of eligible studies in the meta-analyses

From: Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis

Study Year Country Study design Sample size Male/ Female ratio Mean age Histology (clear cell%) Survival analysis Definition of hypertension Type of analysis TKIs Quality Assessment (NOS Score = 9)
Rini (a) [10] 2011 the USA R 534 2.3 60.6 98% PFS, OS SBP ≥ 140 mmHg, DBP ≥ 90 mmHg multivariate SUN 7
Szmit [12] 2011 Poland R 111 3.0 55.9 100% PFS, OS BP ≥ 140/90 mmHg univariate SUN 9
Bono [17] 2011 Finland R 64 1.7 64 92% PFS BP > 150/100 mmHg OR blood pressure requiring intensifi cation of pre-existing anti-hypertensive medication. multivariate SUN 7
Fujita [18] 2012 Japan R 41 2.7 64 100% PFS univariate SUN 7
Eechoute [19] 2012 Netherlands R 158 1.7 60 87% PFS, OS SBP > 140 mmHg, DBP > 90 mmHg, MAP > 110 mmHg multivariate SUN 7
Rini (b) [13] 2013 the USA R 168 2.5 60 PFS, OS DBP ≥90 mmHg multivariate AXI 7
Motzer (a) [20] 2013 the USA P 350 2.8 61 100% PFS, OS SBP > 140 mmHg, DBP > 90 mmHg multivariate AXI 6
Motzer (b) [20] 2013 the USA P 336 2.5 61 100% PFS, OS SBP > 140 mmHg, DBP > 90 mmHg multivariate SOR 6
Hong [21] 2013 China R 136 2.0 56 93% OS Hypertension class III/IV multivariate SUN 7
Nakano [22] 2013 Japan R 36 3.5 65.8 61% PFS grade 1–3 (NCI-CTCAE, version 3.0) multivariate SOR 7
Fujita [23] 2014 Japan R 44 2.7 63.5 95% PFS multivariate SUN 7
Eto [24] 2014 Japan R 64 2.2 63 97% OS DBP ≥90 mmHg AXI 7
Rini (c) [25] 2015 the USA P 203 2.0 61.9 PFS DBP change from baseline ≥10/15 mmHg AXI 7
Zhang (a) [26] 2015 China R 256 2.5 58 79% OS multivariate SOR 7
Kucharz [27] 2015 Poland R 28 2.1 65 PFS office SBP ≥140 and/or DBP ≥90 mmHg; home SBP ≥135 and/or DPB ≥85 mmHg; pre-existing medication-controlled arterial hypertension and required additional antihypertensive medication during treatment multivariate SUN 7
Izzedine [28] 2015 France R 212 3.4 57.7 86% PFS, OS multivariate SUN 8
Donskov [29] 2015 the USA R 770 2.6 60 98% PFS SBP ≥ 140 mmHg multivariate SUN 7
Zhang (b) [30] 2016 China R 134 2.4 59.8 77% OS multivariate SOR 7
Goldstein (a) [14] 2016 Australia R 479 2.2 59.5 PFS, OS MAP change from baseline>10 mmHg univariate PAZ 9
Goldstein (b) [14] 2016 Australia R 506 2.6187 61 PFS, OS SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg univariate PAZ 9
Goldstein (c) [14] 2016 Australia R 475 3.3394 60.9 PFS, OS SBP > 140 mm H, DBP > 90 mmHg, MAP change from baseline>10 mmHg, SBP change from baseline>10 mmHg univariate SUN 9
Cecere [31] 2016 Italy R 38 1.375 61 84.2% OS grade ≥ 3 (NCI-CTCAE, version 4.0) multivariate PAZ 7
Miyake [32] 2016 Japan R 50 4.0000 64 80% PFS SBP ≥ 140 or DBP ≥ 90 mmHg multivariate SUN 7
Fukuda [15] 2016 Japan R 62 2.4444 66 92% PFS, OS univariate SUN 7
Matias [33] 2017 France P 106 2.3125 54 90% PFS, OS grade ≥ 3 (NCI-CTCAE, version 4.0) univariate AXI 7
  1. R Retrospective, P Prospective, PFS Progression-free survival, OS Overall survival, SBP Systolic blood pressure, DBP Diastolic blood pressure, MAP ≈ 2/3 DBP + 1/3 SBP; SUN Sunitinib, AXI Axitinib, SOR Sorafenib, PAZ Pazopanib, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
  2. —: The data were not available in this study